Atlas Trials

Anlotinib Plus Penpulimab as Second-line Treatment for Patients With Small Cell Lung Cancer After Failure of Platinum-based Chemotherapy

Clinical trial NCT05001971 · COMPLETED

Trial details

NCT number
NCT05001971
Sponsor
Hunan Cancer Hospital
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Small Cell Lung Cancer
Start date
2021-01-30
Primary completion
2025-01-21
Enrollment
65

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.